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Introduction
Heat-shock proteins (HSPs), known as evolutionarily 
highly conserved stress-inducible proteins, play an 
important role in regulating cellular homeostasis by 
means of refolding of damaged proteins and inhibiting 
accumulation of protein aggregates (Georgopoulos and 
Welch, 1993; Becker and Craig, 1994; Hartl and Hayer-
Hartl, 2002). Heat shock protein 70 (HSP70), one of the 
most well-known HSPs, function as key components not 
only in cellular homeostasis, but also in upregulation 
of pro-inflammatory cytokines and antigen processing 
and presentation (DeNagel and Pierce, 1992; Asea et al., 
2000). It has been demonstrated that HSP70 expression 
is abnormally high in cancer cells and it may be involved 
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Abstract
 Background: Previous epidemiological studies have suggested a potential role of the HSPA1B±1267A/G 
polymorphism in risk of developing cancer. However, the results were inconsistent. Therefore, we performed 
this meta-analysis to summarize the possible association with cancer risk. Materials and Methods: We retrieved 
relevant articles from PubMed, EMBASE, ISI Web of Science, Chinese Biomedical Literature and Chinese 
National Knowledge Infrastructure. Studies were selected using specific criteria. Odds ratios (ORs) with 95% 
confidence intervals (CIs) were calculated to assess those associations. All analyses were performed using STATA 
software. Results: Fourteen case-control studies, including 1, 834 cancer cases and 2, 028 controls were included 
in this meta-analysis. Overall, the results indicated that the G allele of HSPA1B gene ±1267A/G was significantly 
associated with an increased cancer risk in all genetic models (G vs A: OR=1.51, 95%CI 1.17-1.95, p=0.001; GG 
vs AA: OR=2.93, 95%CI 1.50-5.74, p=0.002; AG vs AA: OR=1.48, 95%CI 1.10-1.98, p=0.009; GG/AG vs AA: 
OR=1.69, 95%CI 1.22-2.33, p=0.001; GG vs AG/AA: OR=2.31, 95%CI 1.24-4.32, p=0.009). In the subgroup 
analysis stratified by ethnicity, a significant association was identified in Caucasians (G vs A: OR=1.35, 95%CI 
1.08-1.69, p=0.008; GG/AG vs AA: OR=1.36, 95%CI 1.09-1.70, p=0.007), but not in Asians. In the stratified 
analysis by cancer types, individuals with the G allele showed an increased risk of hepatocellular carcinoma 
compared with carriers of the A allele (OR=2.40, 95%CI 1.47-3.91, p< 0.001). Inversely, individuals with the 
GG genotype showed a decreased risk of gastric cancer compared with carriers of the AG/GG genotypes (GG 
vs AG/AA: OR=0.39, 95%CI 0.20-0.70, p=0.007). Conclusions: This meta-analysis suggests associations between 
the HSPA1B ±1267A/G polymorphism and risk of cancer. However, this association might be Caucasian-specific 
and the G allele of this polymorphism probably increases risk of hepatocellular carcinoma while decreasing 
risk of gastric cancer. Further well-designed studies based on larger sample sizes are needed to validate these 
findings. 
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in oncogenesis and protecting malignant cells against 
host immunologic reactions (Radons and Multhoff, 
2005; Calderwood et al., 2006; Garrido et al., 2006). 
Thus, HSP70 plays a critical role in tumor promotion, 
treatment and prognosis (Ciocca et al., 1993; Ciocca and 
Calderwood, 2005; Anand et al., 2011; Khalil et al., 2011; 
Cai et al., 2013; Wang et al., 2014). 
HSPA1B, encodes HSP70-2 which is a component 
of HSP70, is located in the class Ⅲ region of the human 
major histocompatibility complex (MHC) on chromosome 
6p21.3 (Milner and Campbell, 1992). Published genome-
wide association studies in Caucasians have reported that 
several polymorphisms were associated with cancer risk in 
this region (Hung et al., 2008; Wang et al., 2008; Broderick 
et al., 2009), and the HSPA1B ±1267A/G polymorphism 
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justly located in this region was most widely studied. 
It has reported that the HSPA1B ±1267A/G variant can 
regulate the expression of HSP70-2 by interfering with 
the secondary structure and stability of mRNA (Schroeder 
et al., 1999; Wu et al., 2004), thus may affect its anti-
apoptotic and immune modulator function, therefore, 
resulting in predisposition to and prognosis of cancers.
A number of epidemiological studies have examined 
the association between this ±1267A/G polymorphism 
and cancer risk (Chouchane et al., 1997; Mestiri et al., 
2001; Jalbout et al., 2003; Toth et al., 2007; Jeng et 
al., 2008; Rehman et al., 2009; Shibata et al., 2009; Li 
et al., 2010; Wang et al., 2010; Srivastava et al., 2012; 
Zagouri et al., 2012; Ferrer-Ferrer et al., 2013; Medhi 
et al., 2013). However, the results were inconclusive or 
even contradictory which may be due to small sample 
size, different ethnic populations and cancer types in the 
corresponding studies. Therefore, we performed a meta-
analysis followed by stratified analysis of all eligible 
studies to systematically clarify the association between 
the HSPA1B ±1267A/G polymorphism and cancer risk.
Materials and Methods
Literature Search
A comprehensive search of five electronic databases, 
including PubMed, EMBASE, ISI Web of Science, 
Chinese Biomedical Literature (CBM) and Chinese 
National Knowledge Infrastructure (CNKI), for all studies 
published through December 31, 2013, that had examined 
the association between HSPA1B ±1267 polymorphism 
and cancer risk. The following search terms and their 
synonyms were used: “heat shock protein70 or hsp70 or 
HSPA1B”, “gene or polymorphism or allele or variation”, 
“cancer or carcinoma or neoplasm or tumor”. References 
lists in retrieved articles were also screened. We included 
published articles on relevant studies carried out in human 
subjects in all languages.
Inclusion and Exclusion Criteria
Eligible studies for further meta-analysis had to meet 
all of the following criteria: (1) case-control study design; 
(2) investigating the association between ±1267A/G 
polymorphism and cancer risk; (3) describing detail 
genotype frequencies in case and control groups so that 
an odds ratio (OR) with 95% confidence interval (CI) 
could be calculated. The major exclusion criteria were: 
(1) duplicate of previous publication; (2) abstract, review, 
comment and editorial; (3) animal studies; (4) family or 
sibling pairs based studies; (5) sufficient original genotype 
frequencies were unavailable, even contacting the 
corresponding author of the relevant articles. If there was 
more than one study published by the same investigators 
using the same or overlapping data, we selected the article 
involving complete design and larger sample size.
Data extraction
Two reviewers (Kuang and Yu) independently 
extracted the following information from the eligible 
studies: first author’s surname, year of publication, 
country of origin, ethnicity, source of control, cancer type, 
genotyping method, sample size of genotyped cases and 
controls, genotype frequencies in case and control groups. 
If the study involving more than one type of cancer, data 
were extracted separately as independent studies. Any 
disagreements on the data extracted by the two reviewers 
were resolved by discussion until reaching conformity on 
all items among all authors.
Statistical analysis
Firstly, we assessed the genotype frequencies of 
±1267A/G polymorphism for HWE in control groups by 
Chi-square test and a p<0.05 was considered as significant 
disequilibrium (Schaid and Jacobsen, 1999). The strength 
of the association between ±1267A/G polymorphism and 
cancer risk was calculated by OR with its 95%CI. The 
pooled ORs and their 95%CI in each comparison were 
performed for allelic comparison (G vs A), homozygote 
model (GG vs AA), heterozygote model (AG vs AA), 
dominant model (GG/AG vs AA) and recessive model 
(GG vs AG/AA), respectively. The Z test was conducted 
to determine the significance of the pooled ORs. As there 
were multiple comparisons, bonferroni correction was 
used to adjust the significance alpha level, and p<0.01 
was considered statistically significant. The chi-square 
based Cochran’s Q test and I2 statistics were employed to 
assess the between-study heterogeneity and heterogeneity 
was considered to be significant when p<0.10 in Q test 
(Higgins and Thompson, 2002; Zintzaras and Ioannidis, 
2005). The fixed-effects model (based on Mantel-
Haenszel method) was applied to calculate the pooled 
ORs when the P value for Q statistic was larger than 
0.10; otherwise, the random-effects model (based on 
DerSimoniane-Laird method) was used (DerSimonian 
and LairdN, 1986). Secondly, in order to explore the 
source of heterogeneity, we performed sub-group analyses 
as well as meta-regression among variables, including 
ethnicity (Caucasian and Asian), cancer types (if one 
cancer type contained less than two individual studies, 
it was combined into other cancer subgroups), source of 
control (population-based and hospital-based) and HWE, 
respectively (Higgins and Thompson, 2004). Thirdly, we 
carried out sensitivity analysis to evaluate the influence 
of each study on the overall estimate by sequentially 
removing individual study. Finally, we conducted 
Funnel plot and Egger’s linear regression test to examine 
potential publication bias, and p<0.05 was considered 
to be statistically significant publication bias (Begg and 
Mazumdar, 1994; Egger et al., 1997; Peters et al., 2006). 
All P values were two sided, and all statistical analyses 
were conducted by using STATA statistical software 
(version 11.0; StataCorp, College Station, Texas USA). 
Results
Characteristics of eligible studies
The flow chart in Figure 1 displayed the comprehensive 
literature search and study selection procedures for 
HSPA1B ±1267A/G polymorphism and cancer risk. After 
careful search and selection, 13 eligible publications 
were identified according to inclusion criteria. Besides, 
the publication reported by Chouchane et al. applied two 
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different cancer groups (non-Hodgkin’s lymphoma and 
breast cancer) with the same set of control, which was 
considered as two case-control studies. Finally, a total 
of 14 case-control studies with 1, 834 cases and 2, 028 
controls were enrolled in our meta-analysis. The main 
characteristics of each study were summarized in Table 1. 
Among the 14 applicable studies, 7 of them were carried 
out in Asian populations and 7 in Caucasian populations. 
In view of control source, 12 studies were population-
based, 1 study was hospital-based, and 1 study was not 
Table 1. Characteristics of the Eligible Studies in the Meta-analysis
Study year Country Ethnicity Cancer type Control source No. of Case Control HWE
 case/control AA AG GG AA AG GG 
Maura 2013 Costa Rica Caucasian Gastric PB 39/79 6 26 7 17 32 30 Y
Medhi 2013 India Asian Hepatocellular Not described 185/200 111 59 15 156 40 4 Y
Zagouri 2012 Greece Caucasian Breast PB 113/124 24 82 7 32 76 16 N
Srivastava 2012 India Asian Pancreatic PB 50/50 13 29 8 33 15 2 Y
Wang 2010 China Asian Lung PB 159/202 57 72 30 56 100 46 Y
Rehman 2009 India Asian Skin PB 118/95 10 103 5 24 70 1 N
Jeng 2008 China Asian Hepatocellular PB 150/150 28 55 67 70 65 15 Y
Toth 2007 Hungary Caucasian Colorectal PB 183/141 69 87 27 65 57 19 Y
Jalbout 2003 Tunisia Caucasian Nasopharyngeal PB 140/274 40 68 32 101 138 35 Y
Mestiri 2001 Tunisia Caucasian Breast PB 243/174 52 123 68 35 130 9 N
Chouchane 1997 Tunisia Caucasian non-Hodgkin’s PB 44/106 4 28 12 22 82 2 N
Chouchane 1997 Tunisia Caucasian Breast PB 40/106 4 26 10 22 82 2 N
Li 2010 China Asian Hepatocellular PB 145/127 48 71 26 56 62 9 Y
Shibata 2009 Japan Asian Gastric HB 223/200 46 173 6 33 155 12 N
*PB: population-based; HB: hospital-based; HWE: Hardy-Weinberg equilibrium
Table 2. Meta-analysis of the Association Between the Hspa1b +1267A/G Polymorphism and Cancer Risk in 
All Genetic Models
 Comparisons N Test of association Test of heterogeneity 
   OR (95%CI) P value Model  P value I2 (%)
Overall G vs A 14 1.51 (1.17-1.95) 0.001  R  < 0.001 85.2 
 GG vs AA 14 2.93 (1.50-5.74) 0.002  R  < 0.001 85.2 
 AG vs AA 14 1.48 (1.10-1.98) 0.009  R  < 0.001 68.3 
 GG/AG vs AA 14 1.69 (1.22-2.33) 0.001  R  < 0.001 76.1 
 GG vs AG/AA 14 2.31 (1.24-4.32) 0.009  R  < 0.001 86.5 
Overall for HWE G vs A 8 1.62 (1.09-2.40) 0.017  R  < 0.001 89.2 
 GG vs AA 8 2.55 (1.18-5.51) 0.018  R  < 0.001 85.7 
 AG vs AA 8 1.60 (1.13-2.26) 0.008  R  0.004  66.6 
 GG/AG vs AA 8 1.83 (1.20-2.80) 0.005  R  < 0.001 80.3 
 GG vs AG/AA 8 0.52 (0.26-1.03) 0.062  R  < 0.001 85.4 
Ethnicity        
  Asian G vs A 7 1.70 (1.06--2.73) 0.026  R  < 0.001 91.8 
 GG vs AA 7 3.12 (0.99-9.77) 0.051  R  < 0.001 89.4 
 AG vs AA 7 1.67 (1.03-2.71) 0.037  R  < 0.001 80.1 
 GG/AG vs AA 7 1.96 (1.10-3.51) 0.023  R  < 0.001 87.4 
 GG vs AG/AA 7 2.31 (1.24-4.32) 0.069  R  < 0.001 85.8 
  Caucasian G vs A 7 1.35 (1.08-1.69) 0.008  R  0.026  58.2 
 GG vs AA 7 2.76 (1.18-6.49) 0.020  R  < 0.001 81.0 
 AG vs AA 7 1.21 (0.96-1.52) 0.110  F  0.140  37.8 
 GG/AG vs AA 7 1.36 (1.09-1.70) 0.007  F  0.562  0.0 
 GG vs AG/AA 7 2.33 (0.89-6.10) 0.084  R  < 0.001 88.8 
Cancer type        
  Gastric G vs A 2 0.84 (0.66-1.07) 0.159  F  0.671  0.0 
 GG vs AA 2 0.46 (0.21-1.04) 0.061  F  0.466  0.0 
 AG vs AA 2 1.21 (0.44-3.35) 0.704  R  0.078  67.8 
 GG/AG vs AA 2 0.88 (0.57-1.36) 0.564  F  0.245  26.1 
 GG vs AG/AA 2 0.39 (0.20-0.77) 0.007  F  0.793  0.0 
  Hepatocellular G vs A 3 2.40 (1.47-3.91) < 0.001 R  0.004  82.1 
 GG vs AA 3 6.07 (2.80-13.19) < 0.001 R  0.098  57.0 
 AG vs AA 3 1.80 (1.34-2.42) < 0.001 F  0.377  0.0 
 GG/AG vs AA 3 2.41 (1.51-3.87) < 0.001 R  0.058  64.8 
 GG vs AG/AA 3 4.98 (3.18-7.79) < 0.001 F  0.191  39.6 
  Breast G vs A 3 1.40 (0.95-2.06) 0.091  R  0.042  68.5 
 GG vs AA 3 3.86 (0.56-26.43) 0.169  R  < 0.001 88.0 
 AG vs AA 3 1.06 (0.55-2.05) 0.859  R  0.070  62.5 
 GG/AG vs AA 3 1.16 (0.81-1.64) 0.418  F  0.291  18.9 
 GG vs AG/AA 3 3.62 (0.43-30.28) 0.236  R  < 0.001 92.4 
  Others G vs A 6 1.49 (1.06-2.11) 0.024  R  < 0.001 80.2 
 GG vs AA 6 3.15 (1.21-8.16) 0.018  R  < 0.001 82.9 
 AG vs AA 6 1.71 (1.00-2.92) 0.049  R  0.001  76.3 
 GG/AG vs AA 6 1.88 (1.06-3.31) 0.030  R  < 0.001 81.0 
 GG vs AG/AA 6 2.20 (1.05-4.61) 0.038  R  0.001  76.6 
*adata after excluding those studies’ controls not in Hardy-Weinberg equilibrium; bnumber of sutdies; R: random-effects model; F: fixed-effects model
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mentioned. According to the cancer types, 3 studies focus 
on hepatocellular carcinoma, 3 studies on breast cancer, 
2 studies on gastric cancer and 6 studies on other cancers 
(lung cancer, pancreatic cancer, skin cancer, colorectal 
cancer, nasopharyngeal cancer and non-Hodgkin’s 
lymphoma), respectively. The genotype distributions in 
the controls of 8 studies were consistent with HWE. The 
genotyping method in all studies was polymerase chain 
reaction-restriction fragment length polymorphism.
Meta-analysis
Overall, when all applicable studies were pooled into 
the meta-analysis, we found that the HSPA1B ±1267A/G 
polymorphism was significantly associated with increased 
cancer risk in all genetic models (G vs A: OR=1.51, 95%CI 
1.17-1.95, p=0.001; GG vs AA: OR=2.93, 95%CI 1.50-
5.74, p=0.002; AG vs AA: OR=1.48, 95%CI 1.10-1.98, 
p=0.009; GG/AG vs AA: OR=1.69, 95%CI 1.22-2.33, 
p=0.001; GG vs AG/AA: OR=2.31, 95%CI 1.24-4.32, 
p=0.009). In the subgroup analysis stratified by ethnicity, a 
significantly increased cancer risk was found in Caucasian 
population (G vs A: OR=1.35, 95%CI 1.08-1.69, p=0.008; 
GG/AG vs AA: OR=1.36, 95%CI 1.09-1.70, p=0.007), 
but not in Asian population. When stratified by cancer 
type, the G allele was associated with an increased risk 
of hepatocellular carcinoma in all genetic models (G vs 
A: OR=2.40, 95% CI 1.47-3.91, p<0.001; GG vs AA: 
OR=6.07, 95% CI 2.80-13.19, p<0.001; AG vs AA: 
OR=1.80, 95% CI 1.34-2.42, p<0.001; GG/AG vs AA: 
OR=2.41, 95% CI 1.51-3.87, p<0.001; GG vs AG/AA: 
OR=4.98, 95% CI 3.18-7.79, p<0.001), while it seemed 
to be protective against gastric cancer (GG vs AG/AA: 
OR=0.39, 95%CI 0.20-0.70, p=0.007) (Table 2). 
Heterogeneity analysis
There was significant heterogeneity among included 
studies in all comparison models (PQ<0.001 for all). Thus, 
we conducted subgroup analyses to explore the sources of 
heterogeneity. Although the results of subgroup analyses 
showed the heterogeneity was still significant in Asian 
populations and other cancer types, the heterogeneity 
Figure 1. Flow diagram of the study selection process. 
*one publication included two types of cancers, we extracted 
data separately for each cancer, thus 14 studies were included
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Table 3. Egger’s Linear Regression Test to Measure the Funnel Plot Asymmetric
 Groups Egger’s test: t value (P value)
 G vs A GG vs AA AG vs AA GG/AG vs AA GG vs AG/AA
Overall 1.30 (0.219) 1.31 (0.216) 2.09 (0.059) 1.57 (0.143) 0.86 (0.409)
Overall for HWE 0.58 (0.580) 0.79 (0.459) 1.73 (0.134) 1.01 (0.349) 0.44 (0.674)
Caucasian -0.10 (0.921) 0.97 (0.378) 1.40 (0.221) 1.71 (0.147) 0.62 (0.561)
Asian 1.79 (0.133) 0.77 (0.475) 2.31 (0.069) 1.56 (0.179) 0.50 (0.640)
Hepatocellular carcinoma -0.44 (0.736) -0.68 (0.618) -0.03 (0.983) 0.41 (0.753) 0.69 (0.614)
Breast cancer 0.16 (0.900) 0.35 (0.786) 1.02 (0.494) 3.71 (0.168) 0.10 (0.934)





































































































Table 4. ORs (95% CI) of Sensitivity Analysis
Excluding literature  G vs. A GG vs. AA AG vs. AA GG/AG vs. AA GG vs. AG/AA
one by one OR (95% CI)  OR (95% CI) OR (95% CI)  OR (95% CI)  OR (95% CI)
Over all 1.51 (1.17-1.95) 2.93 (1.50-5.74) 1.47 (1.10-1.97) 1.69 (1.22-2.32) 2.31 (1.23-4.32)
Ferrer-Ferrer (2013) 1.58 (1.22-2.05) 3.28 (1.63-6.60) 1.45 (1.07-1.95) 1.70 (1.21-2.38) 2.67 (1.43-5.00)
Medhi (2013) 1.46 (1.12-1.90) 2.81 (1.38-5.71) 1.43 (1.05-1.94) 1.64 (1.16-2.30) 2.21 (1.14-4.27)
Zagouri (2012) 1.57 (1.20-2.05) 3.34 (1.67-6.69) 1.49 (1.08-2.04) 1.73 (1.22-2.44) 2.63 (1.39-4.98)
Srivastava (2012) 1.44 (1.12-1.85) 2.71 (1.36-5.42) 1.36 (1.04-1.79) 1.56 (1.14-2.12) 2.22 (1.16-4.26)
Wang (2010) 1.59 (1.24-2.05) 3.35 (1.71-6.57) 1.57 (1.17-2.10) 1.82 (1.33-2.48) 2.56 (1.32-4.96)
Rehman (2009) 1.51 (1.15-1.99) 2.74 (1.38-5.46) 1.38 (1.04-1.84) 1.60 (1.15-2.21) 2.25 (1.18-4.29)
Jeng (2008) 1.39 (1.12-1.73) 2.54 (1.33-4.85) 1.43 (1.08-2.06) .55 (1.14-2.11) 2.06 (1.11-3.85)
Toth (2007) 1.54 (1.17-2.03) 3.19 (1.52-6.69) 1.49 (1.08-2.06) 1.72 (1.21-2.46) 2.48 (1.25-4.93)
Jalbout (2003) 1.52 (1.15-2.01) 3.06 (1.43-6.55) 1.51 (1.09-2.09) 1.72 (1.20-2.45) 2.37 (1.16-4.83)
Mestiri (2001) 1.51 (1.14-2.00) 2.81 (1.37-5.77) 1.58 (1.19-2.09) 1.78 (1.27-2.50) 2.08 (1.10-3.94)
Chouchane (1997)† 1.48 (1.13-1.92) 2.54 (1.30-4.95) 1.46 (1.08-1.98) 1.65 (1.19-2.30) 2.02 (1.08-3.82)
Chouchane (1997)* 1.48 (1.14-1.93) 2.57 (1.31-5.03) 1.47 (1.08-1.99) 1.66 (1.19-2.32) 2.04 (1.09-3.82)
Li (2010) 1.51 (1.14-1.98) 2.93 (1.41-6.07) 1.50 (1.09-2.06) 1.70 (1.20- .42) 2.28 (1.16-4.93)
Shibata (2009) 1.58 (1.22-2.05) 3.44 (1.75-6.74) 1.56 (1.15-2.11) 1.80 (1.30-2.50) 2.63 (1.39-4.98)
*† study for the non-Hodgkin’s lymphoma.  *study for the breast cancer
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decreased obviously in Caucasian populations (AG 
vs AA: PQ=0.140; GG/AG vs AA: PQ=0.562), gastric 
cancers (G vs A: PQ=0.671; GG vs AA: PQ=0.466; 
GG/AG vs AA: PQ=0.245; GG vs AA/AG: PQ=0.793), 
hepatocellular carcinoma (AG vs AA: PQ=0.377; GG vs 
AA/AG: PQ=0.191), and breast cancer (GG/AG vs AA: 
PQ=0.291) (Table 2). We further identify the source of 
heterogeneity by ethnicity, cancer type and HWE with 
the meta-regression. The results revealed that cancer type 
(p=0.015), but not ethnicity and HWE (p>0.05) contribute 
to the source of heterogeneity.
Sensitivity analysis
In order to test the robustness of the results of the 
meta-analysis, we conducted the sensitivity analysis by 
sequentially omitting each individual study for all genetic 
models. The results indicated that the corresponding 
pooled ORs were not materially altered, which confirmed 
the stability and reliability of our overall results (Table 
4). Furthermore, we performed sensitivity analysis by 
excluding the studies not conforming to HWE. The 
results also showed the corresponding pooled ORs were 
not materially altered in overall comparisons (Table 2). 
Publication bias
We carried out Funnel plot and Egger’s linear 
regression test to assess the potential publication bias 
of the literatures. There was no evidence of funnel plot 
asymmetry observed in any genetic model of overall 
studies and subgroup studies (not shown). And the 
results of Egger’s linear regression test also showed no 
publication bias. Due to small sample size, the Egger’s 
linear regression test was not available for gastric cancer 
(Table 3). 
Discussion
HSP70 is a key chaperone protein that regulates 
cellular homeostasis in tumor microenvironment and 
is over expressed on the surface of tumor cells, which 
induces antitumor immunorecognition by cytotoxic 
T lymphocytes (Radons and Multhoff, 2005). It has 
the ability to influence tumor cells proliferation and 
survival, participate in tumor immunogenicity, and confer 
resistance to chemotherapy (Ciocca and Calderwood, 
2005). Human HSP70 gene is located in the class Ⅲ 
region of MHC on chromosome 6p21.3, which contains 
three main genes (HSPA1A, HSPA1B and HSPA1L). The 
most common polymorphisms is at position ±1267 of 
coding region of HSPA1B gene. Several investigators 
have studied the possible association between ±1267A/G 
polymorphism and cancer risk. However, the results were 
inconclusive or even contradictory. In order to obtain a 
more precise estimation of this association, we performed 
a meta-analysis including 14 case-control studies with 
1, 834 cases and 2, 028 controls to systematically 
clarify the association between the HSPA1B ±1267A/G 
polymorphism and cancer risk. In overall meta-analysis, 
the G allele of ±1267A/G polymorphism was found to 
be significantly associated with an increased cancer risk 
in all five genetic models. The G allele of ±1267A/G 
polymorphism may interfere with the secondary structure 
and stability of mRNA, leading to affect the expression 
of HSP70, and thus contributes to the predisposition and 
development of cancers.
We also performed the subgroup analysis to disclose 
the effects of confounding factors. As for the subgroup 
analysis by ethnicity, significantly increased cancer risks 
with G allele of ±1267A/G polymorphism were found 
in Caucasian populations under allelic comparison and 
dominant model. However, there was no association 
between ±1267A/G polymorphism and cancer risk in 
Asian populations. One potential explanation is that 
different ethnicities have various genetic backgrounds, 
which may lead to different degrees of cancer susceptibility 
(Constantinescu et al., 1975). For example, several GWAS 
studies have reported polymorphisms at 6p21.3 were 
associated with lung cancer risk, but they did not exist 
in Asians according to the HapMap project (Hung et al., 
2008; Wang et al., 2008; Broderick et al., 2009). The 
other reason may be that different ethnicities which live 
in different regions have various dietary habits and life-
styles and expose to multiple environmental factors, and 
thus yield diverse gene-environment interactions (Latvala 
et al., 2011; Wu et al., 2012). 
In the subgroup analysis stratified by cancer type, the 
±1267A/G polymorphism demonstrated varied effect on 
predisposition to different types of cancer. We detected 
a significant association between the G allele and an 
increased risk of hepatocellular carcinoma. However, 
an opposite association was found in gastric cancer for 
the GG genotype compared with AG/AA genotypes. 
This can potentially be explained by the following 
reasons. First, different types of cancer may have their 
own genetic etiology. This polymorphism of our interest 
may have different roles in different cancers. Moreover, 
there were only 2 or 3 studies relevant for gastric cancer, 
hepatocellular carcinoma and breast cancer, respectively.
Finally, the huge heterogeneity in this meta-analysis 
should not be ignored. We observed significant between-
study heterogeneity in the pooled analyses in all five 
genetic models. We further conducted subgroup analyses 
to explore the sources of heterogeneity. Subgroup analyses 
stratified by ethnicity and cancer type showed that the 
heterogeneity decreased substantially in Caucasian 
population, and for gastric cancer, hepatocellular 
carcinoma, and breast cancer in some comparison models, 
but remained significant in Asian population as well as 
for other cancer types. Subsequently, we investigated the 
source of heterogeneity by using meta-regression, and 
the results indicated that cancer type, but not ethnicity or 
HWE, contributed to the majority source of heterogeneity. 
Other covariates, such as age, sex, body max index, 
smoking and drinking status, diet habit etc may also induce 
such heterogeneity. However, we could not evaluate 
their potential effects due to the unavailability of data in 
included studies.
Some limitations should also be acknowledged in 
our study when interpreting results. First, although 
overall our analysis included a fairly large sample size 
(1, 834 cases and 2, 028 controls), after stratifying by 
cancer type, the sample size for each specific type of 
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cancer became relatively small, and thus may limited 
the ability to sufficiently explore the associations. 
However, our analysis synthesized evidences from all 
available studies, and further studies with larger power 
are warranted to better characterize these associations. 
Second, heterogeneity in our meta-analysis was huge, 
and meta-regression analysis indicated that cancer type 
can only explain part of this heterogeneity. As a lack of 
data for other potential confounders, we could not explore 
their potential effects. Third, this meta-analysis was based 
on unadjusted estimates, and a more precise estimation 
taking account of other confounders such as age, sex, 
body max index, smoking and drinking status, diet 
habit, family history and environmental exposures could 
potentially more accurately estimate the associations. 
Fourth, not all studies included in our meta-analysis were 
consistent with HWE. Certain considerations, including 
potential laboratory and/or genotyping errors, population 
stratification, and selection bias may apply for those 6 
studies which were deviated from HWE. Interpretation 
of our findings should be cautious considering all these 
limitations.
In conclusion, our meta-analysis supports that the 
HSPA1B gene ±1267A/G polymorphism may contribute 
to susceptibility of cancer, though in a Caucasian-
specific manner. The G allele probably increases risk of 
hepatocellular carcinoma while may be protective from 
gastric cancer. Further well-designed studies with larger 
sample sizes are warranted to validate these findings and 
better clarify these associations.
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